Obesity and Serious Mental Ill Health: A Critical Review of the Literature
Open Access
- 1 April 2014
- journal article
- review article
- Published by MDPI AG in Healthcare
- Vol. 2 (2) , 166-182
Abstract
Individuals who experience serious mental ill health such as schizophrenia are more likely to be overweight or obese than others in the general population. This high prevalence of obesity and other associated metabolic disturbances, such as type 2 diabetes and cardiovascular disease, contribute to a reduced life expectancy of up to 25 years. Several reasons have been proposed for high levels of obesity including a shared biological vulnerability between serious mental ill health and abnormal metabolic processes, potentially compounded by unhealthy lifestyles. However, emerging evidence suggests that the most significant cause of weight gain is the metabolic side effects of antipsychotic medication, usual treatment for people with serious mental ill health. In this paper we review the prevalence of obesity in people with serious mental ill health, explore the contribution that antipsychotic medication may make to weight gain and discuss the implications of this data for future research and the practice of mental health and other professionals.Keywords
This publication has 47 references indexed in Scilit:
- Psychosocial interventions for the negative symptoms of psychosisMental Health Practice, 2013
- Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: A meta-analytic comparison of randomized controlled trialsSchizophrenia Research, 2012
- Evolving role of mental health nurses in the physical health care of people with serious mental health illnessInternational Journal of Mental Health Nursing, 2012
- Prevalence of Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia and Related Disorders—A Systematic Review and Meta-AnalysisSchizophrenia Bulletin, 2011
- A Double Blind, Placebo-Controlled, Randomized Crossover Study of the Acute Metabolic Effects of Olanzapine in Healthy VolunteersPLOS ONE, 2011
- Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trialThe Lancet, 2008
- Antipsychotic-Induced Weight Gain in Chronic and First-Episode Psychotic DisordersCNS Drugs, 2008
- Schizophrenia and increased risks of cardiovascular diseaseAmerican Heart Journal, 2005
- Why do adults with schizophrenia have poorer physical health than the rest of the population?Mental Health Practice, 2005
- Diet, diabetes and schizophrenia: Review and hypothesisThe British Journal of Psychiatry, 2004